AbbVie (ABBV)
(Delayed Data from NYSE)
$201.20 USD
-0.48 (-0.24%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $201.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$201.20 USD
-0.48 (-0.24%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $201.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
Zacks News
AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 3.85% and 0.65%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NOBL
Amgen (AMGN) Beats on Q4 Earnings, 2023 Sales View Disappoints
by Zacks Equity Research
Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.
Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 10.68% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
AbbVie (ABBV) Stock Moves -0.43%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $145.65 in the latest trading session, marking a -0.43% move from the prior day.
Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod
by Zacks Equity Research
The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $148.55, marking a -0.7% move from the previous day.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $152.83, marking a -0.5% move from the previous day.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
Zacks Market Edge Highlights: EXAS, ZM, TSLA, ABBV, ZOM
by Zacks Equity Research
EXAS, ZM, TSLA, ABBV, ZOM have been highlighted in this Market Edge article.
The Stocks Behind 2022's Popular ETFs
by Tracey Ryniec
What stocks do popular ETF managers like Cathie Wood own in their portfolios?
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $159.64, moving -1.25% from the previous trading session.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
CytomX (CTMX) Up 55% on Strategic Partnership With Moderna
by Zacks Equity Research
CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $162.38, marking a +0.48% move from the previous day.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer (PFE) Pentavalent Meningitis Jab BLA Gets FDA Acceptance
by Zacks Equity Research
The FDA assigns a standard review to Pfizer's (PFE) BLA for pentavalent meningococcal vaccine candidate (MenABCWY), with a decision expected in October 2023.
The Zacks Analyst Blog Highlights AbbVie, PepsiCo, Oracle, HSBC Holdings and The Progressive
by Zacks Equity Research
AbbVie, PepsiCo, Oracle, HSBC Holdings and The Progressive are part of the Zacks top Analyst Blog.
AbbVie (ABBV) Stock Moves -0.07%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $162.99, moving -0.07% from the previous trading session.
3 Dividend Kings Nicely Suited for Income Investors
by Derek Lewis
Dividend Aristocrats, companies that have increased their dividend payouts for at least 25 consecutive years, are popular targets among income investors. However, a step above is the elite Dividend Kings group.